15.11.2024 • NewsAmbioPharminvestmentPeptides

Ambiopharm Breaks Ground on $28 Million Expansion

Ambiopharm, a US-based pharmaceutical services company specializing in peptide manufacturing, recently announced the groundbreaking of a 70,000-square-foot (6,504 m2) capacity expansion project at its Shanghai manufacturing site. This $28 million (€26.6 million) project reflects the company’s commitment to serving growing global demand and confidence in China’s vital role in the global pharmaceutical supply chain.

The expansion will feature state-of-the-art fragment-based peptide synthesis capabilities with multiple 1000 L to 3000 L solid-phase and liquid-phase peptide synthesis equipment lines. Once completed, the new space will add significant manufacturing capacity, with the ability to produce over 8 metric tons of crude peptide annually. This output will be further processed utilizing existing downstream peptide purification and isolation capabilities already available at the Shanghai site and to a greater extent at Ambiopharm’s US manufacturing site in North Augusta, South Carolina.

“This expansion underscores our commitment to China and its role in our global operations”, said Brian Gregg, CEO of Ambiopharm. “Our new capabilities will allow us to meet the growing demand for therapeutic peptides and enhance our ability to serve customers throughout the world.”

The new manufacturing capacity is expected to be operational in the second half of 2025. 

Ambiopharm breaking ground at the expansion of its pharmaceutical manufacturing...
Ambiopharm breaking ground at the expansion of its pharmaceutical manufacturing site in Shanghai. © Ambiopharm

Company

Logo:

AmbioPharm, Inc.

1024 Dittman Court
SC 29842 North Augusta
US

Company contact







Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read